Related content

Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis

By Marquis P.   Roux C.   de la Loge C.   Diaz-Curiel M.   Cormier C.   Isaia G.   Badurski J.   Wark J.   Meunier P.  

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 503-510

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of postmenopausal women with osteoporosis with PTH(1–84) for 36 months: treatment extension study

By Zanchetta José R.   Bogado Cesar E.   Cisari Carlo   Aslanidis Spyros   Greisen Hanna   Fox John   Lems Willem  

Current Medical Research and Opinion, Vol. 26, Iss. 11, 2010-11 ,pp. : 2627-2633

Informa Healthcare

Access to resources Recommend Favorite

Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women

By Adami Silvano  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3259-3274

Informa Healthcare

Access to resources Recommend Favorite

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

By Villiers T.   Chines A.   Palacios S.   Lips P.   Sawicki A.   Levine A.   Codreanu C.   Kelepouris N.   Brown J.  

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 567-576

Springer Publishing Company

Access to resources Recommend Favorite

How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis

By Marie P.   Felsenberg D.   Brandi M.  

Osteoporosis International, Vol. 22, Iss. 6, 2011-06 ,pp. : 1659-1667

Springer Publishing Company

Access to resources Recommend Favorite